-+ 0.00%
-+ 0.00%
-+ 0.00%

SAB Biotherapeutics shareholders elect four Class II directors at annual meeting

PUBT·06/18/2026 20:36:01
Listen to the news
SAB Biotherapeutics shareholders elect four Class II directors at annual meeting
  • SAB Biotherapeutics held its annual shareholder meeting on June 18, 2026.
  • Shareholders elected four directors: Dr. David Zaccardelli, Katie Ellias, David Link, Andrew Moin.
  • Shareholders ratified EisnerAmper LLP as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-275976), on June 18, 2026, and is solely responsible for the information contained therein.